Page 130 - 《中国药房》2024年12期
P. 130
[ 4 ] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会 [13] 胡志强,余文韬,姚文秀,等. 抗肿瘤药物致心脏毒性及
(CSCO)乳腺癌诊断和治疗指南 2022[M]. 北京:人民健 其防治措施的研究进展[J]. 中国药房,2020,31(2):
康出版社,2022:95-103. 250-256.
Guidelines Working Committee of the Chinese Society of HU Z Q,YU W T,YAO W X,et al. Research progress on
Clinical Oncology. Chinese Society of Clinical Oncology cardiotoxicity caused by antineoplastic drugs and its pre‐
(CSCO)guidelines for the diagnosis and treatment of vention and treatment measures[J]. China Pharm,2020,31
breast cancer 2022[M]. Beijing:People’s Health Publi- (2):250-256.
shing House,2022:95-103. [14] O’BRIEN M E R,WIGLER N,INBAR M,et al. Reduced
[ 5 ] 张剑 . 中国蒽环类药物治疗乳腺癌专家共识[J]. 癌症, cardiotoxicity and comparable efficacy in a phase Ⅲ trial
2021,40(11):475-485. of pegylated liposomal doxorubicin HCl(CAELYX/Doxil)
ZHANG J. Expert consensus of anthracycline drugs in the versus conventional doxorubicin for first-line treatment of
treatment of breast cancer in China[J]. Chin J Cancer, metastatic breast cancer[J]. Ann Oncol,2004,15(3):
2021,40(11):475-485. 440-449.
[ 6 ] LOTRIONTE M,BIONDI-ZOCCAI G,ABBATE A,et [15] CHEN S,WU F,HAI R,et al. Thyroid disease is asso-
al. Review and meta-analysis of incidence and clinical pre‐ ciated with an increased risk of breast cancer:a systematic
dictors of anthracycline cardiotoxicity[J]. Am J Cardiol, review and meta-analysis[J]. Gland Surg,2021,10(1):
2013,112(12):1980-1984. 336-346.
[ 7 ] RENEHAN A G,HARVIE M,CUTRESS R I,et al. How [16] 岑福俊,杨剑波. 乳腺癌患者甲状腺激素和自身抗体的
to manage the obese patient with cancer[J]. J Clin Oncol, 水平及临床意义[J]. 癌症进展,2019,17(18):2180-
2016,34(35):4284-4294. 2182,2191.
[ 8 ] MICHEL L,MINCU R I,MAHABADI A A,et al. Tropo‐ CEN F J,YANG J B. The levels and clinical significance
nins and brain natriuretic peptides for the prediction of car‐ of thyroid hormone and autoantibody in breast cancer pa‐
diotoxicity in cancer patients:a meta-analysis[J]. Eur J tients[J]. Oncol Prog,2019,17(18):2180-2182,2191.
Heart Fail,2020,22(2):350-361. [17] KLEIN HESSELINK E N,KLEIN HESSELINK M S,
[ 9 ] ROBERT J,MORVAN V L,SMITH D,et al. Predicting DE BOCK G H,et al. Long-term cardiovascular mortality
drug response and toxicity based on gene polymorphisms in patients with differentiated thyroid carcinoma:an obser‐
[J]. Crit Rev Oncol Hematol,2005,54(3):171-196. vational study[J]. J Clin Oncol,2013,31(32):4046-4053.
[10] MACEDO A V S,HAJJAR L A,LYON A R,et al. Effi‐ [18] LIM H J,AHN S H,HONG S,et al. The relationship be‐
cacy of dexrazoxane in preventing anthracycline cardio‐ tween subclinical thyroid disease and cardiovascular di-
toxicity in breast cancer[J]. JACC Cardio Oncol,2019,1 sease risk score in Koreans[J]. J Korean Med Sci,2017,32
(1):68-79. (10):1626-1632.
[11] CORREMANS R,ADÃO R,DE KEULENAER G W,et [19] HAUGEN B R,ALEXANDER E K,BIBLE K C,et al.
al. Update on pathophysiology and preventive strategies 2015 American Thyroid Association management guide‐
of anthracycline-induced cardiotoxicity[J]. Clin Exp Phar‐ lines for adult patients with thyroid nodules and differen-
macol Physiol,2019,46(3):204-215. tiated thyroid cancer:the American Thyroid Association
[12] LIPSHULTZ S E,GIANTRIS A L,LIPSITZ S R,et al. guidelines task force on thyroid nodules and differentiated
Doxorubicin administration by continuous infusion is not thyroid cancer[J]. Thyroid,2016,26(1):1-133.
cardioprotective:the Dana-Farber 91-01 acute lympho‐ (收稿日期:2023-12-18 修回日期:2024-05-11)
blastic leukemia protocol[J]. J Clin Oncol,2002,20(6): (编辑:孙 冰)
1677-1682.
· 1532 · China Pharmacy 2024 Vol. 35 No. 12 中国药房 2024年第35卷第12期